Use Code: WF26 And Get 30% OFF, T&C Applay | Get Free Delivery With No Minimum Order

Frequently bought together
GLOCLAV 1/G FC TAB 14/FC TAB
- Sku : I-002528
Key features
GLOCLAV 1/G FC TAB is a film-coated tablet containing amoxicillin 875 mg and clavulanic acid 125 mg. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, while clavulanic acid irreversibly inhibits beta‑lactamase enzymes, protecting amoxicillin from degradation and broadening its activity. It is indicated for treatment of susceptible bacterial infections including upper and lower respiratory tract infections (sinusitis, otitis media, acute exacerbations of chronic bronchitis, pneumonia), urinary tract infections, and skin and soft tissue infections, with other indications as per local label. Available as film-coated tablets in packs of 14.- Brand: GLOCLAV
- Active Ingredient: AMOXICILLIN 875mg, CLAVULANIC ACID 125mg
- Strength: 875,125mg
- Dosage Form: Film-coated tablet
- Pack Size: 14 Tablets
- Route: Oral use
- Prescription Status: Prescription
- Therapeutic Class: Anti-infective
- Pharmacological Group: Penicillin + Beta-lactamase Inhibitor
- Drug Class: Aminopenicillin (beta‑lactam antibiotic) plus beta‑lactamase inhibitor combination.
- Manufacturer: GLOBAL PHARMA
- Country of Origin: United Arab Emirates
- SFDA Registration No.: 0901244687
- Shelf Life: 36 months
- Storage: store below 30°c
- Spectrum: Broad-spectrum
- Antibiotic Class: Penicillin
Frequently bought together
Indications
Approved Uses
Treatment of susceptible bacterial infections such as: upper/lower respiratory tract infections (e.g., sinusitis, otitis media, acute exacerbation of chronic bronchitis, pneumonia), urinary tract infections, and skin/soft tissue infections; other indications may be included per local label (e.g., dental infections).
Dosage & Administration
Dosing by Condition
Adults (typical): 875/125 mg orally every 12 hours (or 500/125 mg every 8 hours as an alternative regimen) for most susceptible infections; duration is indication- and severity-dependent (commonly ~5-7 days for many RTIs, longer for complicated infections per guidelines).
Initial Dose
875mg/125mg (one tablet) every 12 hours
Maintenance Dose
One 875mg/125mg tablet every 12 hours.
Maximum Dose
For the 875/125 mg tablet: usual maximum is 1 tablet every 12 hours (1750 mg amoxicillin/250 mg clavulanate per day); higher amoxicillin daily doses (e.g., 4 g/day) require different formulations with lower clavulanate per gram and are not achieved by increasing 875/125 mg tablet frequency.
Children's Dosage
Children ≥40kg: use adult dose. Children <40kg: 25-45mg/kg/day of amoxicillin component divided every 12 hours (using appropriate suspension formulation). For otitis media, sinusitis, lower respiratory tract infections: 40-45mg/kg/day in divided doses. Neonates and infants <3 months: 30mg/kg/day divided every 12 hours (suspension only).
Dose Adjustment Notes
Renal: dose adjustment is required in renal impairment; the 875/125 mg tablet is not recommended when CrCl <30 mL/min-use lower amoxicillin/clavulanate strengths and/or extended intervals. Hepatic: use with caution and monitor liver function; avoid re-challenge if prior amoxicillin/clavulanate-associated cholestatic jaundice/hepatitis.
How to Take
Oral: swallow the 875/125 mg film‑coated tablet whole with water at the start of a meal; take doses at evenly spaced intervals as prescribed (commonly every 12 hours in adults); do not crush or chew.
Side Effects
Common Side Effects
Common: diarrhea, nausea, vomiting; may also occur: abdominal discomfort, rash/urticaria, and candidiasis (e.g., vaginal/oral).
Side Effect Frequency
Very common (≥10%): diarrhea. Common (1-10%): nausea, vomiting, abdominal pain/indigestion, rash/urticaria/pruritus, mucocutaneous candidiasis (e.g., vaginal/oral). Uncommon (0.1-1%): dizziness, headache, transient liver enzyme elevations. Rare/very rare: cholestatic hepatitis/jaundice, severe cutaneous adverse reactions (SJS/TEN/EM), anaphylaxis, C. difficile-associated colitis, blood dyscrasias (e.g., leukopenia, thrombocytopenia), seizures (especially with renal impairment), interstitial nephritis.
Safety & Warnings
Contraindications
Contraindicated in: (1) hypersensitivity to amoxicillin, clavulanic acid, penicillins, or other beta-lactams (e.g., cephalosporins/carbapenems) including severe immediate reactions; (2) history of cholestatic jaundice/hepatic dysfunction associated with prior amoxicillin/clavulanate.
Warnings & Precautions
Key precautions: assess beta-lactam allergy/cross-reactivity; counsel to seek care for rash, facial swelling, or breathing difficulty; monitor for severe/persistent diarrhea (possible C. difficile); use caution and monitor LFTs in hepatic dysfunction or prolonged therapy; adjust/avoid high-strength tablets in renal impairment; risk of superinfection with prolonged use; avoid in infectious mononucleosis due to high rash risk.
Age Restriction
Generally intended for adults and adolescents/children weighing ≥40 kg; younger/lower-weight children should use pediatric formulations (suspension or lower-strength tablets) dosed by weight.
Drug Interactions
Food Interaction
Take at the start of a meal; food improves GI tolerability and helps optimize clavulanate absorption (overall exposure is not clinically reduced).
Special Populations
Children
Children ≥40kg: use adult dose. Children <40kg: 25-45mg/kg/day of amoxicillin component divided every 12 hours (using appropriate suspension formulation). For otitis media, sinusitis, lower respiratory tract infections: 40-45mg/kg/day in divided doses. Neonates and infants <3 months: 30mg/kg/day divided every 12 hours (suspension only).
Elderly
Standard adult dosing; however, monitor renal function as age-related decline in renal function may necessitate dose adjustment. Use with caution due to increased risk of antibiotic-associated diarrhea.
Kidney Impairment
CrCl ≥30 mL/min: no adjustment for 875/125 mg q12h; CrCl <30 mL/min: do NOT use the 875/125 mg tablet-use lower-strength formulations with extended intervals (e.g., 500/125 mg q12h for CrCl 10-30; 500/125 mg q24h for CrCl <10; add supplemental dosing around hemodialysis per local protocol).
Liver Impairment
No specific dose adjustment is defined; use with caution in hepatic impairment and monitor liver function, and avoid/re-challenge is contraindicated if there is a history of amoxicillin/clavulanate-associated cholestatic jaundice/hepatic dysfunction.
Storage & Patient Advice
Stopping the Medicine
Complete the prescribed course unless a clinician advises stopping (e.g., severe allergy, severe diarrhea, or liver injury symptoms).
Overdose
Overdose may cause GI upset (nausea/vomiting/diarrhea), fluid/electrolyte disturbances, crystalluria/renal impairment, and rarely seizures (especially with renal dysfunction); management is supportive with hydration, stop the drug, and hemodialysis can enhance removal in severe cases.
Patient Counseling
Complete the full course as prescribed. Take 1 tablet at the start of a meal (or with food) to reduce GI upset; doses are typically spaced every 12 hours for the 875/125 mg tablet unless your prescriber directs otherwise. Swallow with water; do not crush/chew unless advised. Seek urgent care for allergy symptoms (rash, swelling, breathing difficulty) and contact a clinician for severe/persistent watery diarrhea (possible C. difficile). Tell your prescriber about prior penicillin/cephalosporin allergy and any kidney or liver disease; do not share antibiotics or keep leftovers.
Monitoring Requirements
Short courses in healthy patients: usually no routine labs. If prolonged therapy and/or hepatic/renal impairment: monitor renal function and liver function tests; consider CBC with prolonged use; monitor INR if on warfarin; monitor for hypersensitivity, severe diarrhea/C. difficile, and superinfection.
Pharmacology
Mechanism of Action
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Clavulanic acid irreversibly inhibits beta-lactamase enzymes produced by resistant bacteria, protecting amoxicillin from degradation and extending its spectrum of activity.
Duration of Effect
Approximately supports an 8-12 hour dosing interval (for this 875/125 mg immediate‑release tablet, typically every 12 hours in adults with normal renal function).
Product Information
Available Dosage Forms
For this SFDA-registered product: film‑coated tablet (oral).
Composition per Dose
Each film-coated tablet: Amoxicillin 875mg (as amoxicillin trihydrate) + Clavulanic acid 125mg (as potassium clavulanate)
Generic Availability
Yes
OTC Alternatives
No OTC alternative - prescription required for all amoxicillin/clavulanate products
Spectrum
Broad-spectrum
Antibiotic Class
Penicillin
Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 14-07-2026
-1744229570.gif)













